SCHEMBL4763429

SCHEMBL4763429

CCN1CCN(c2nc(Br)cc3ccccc23)CC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.53
LMNA P02545 1/20 0.53
MAPT P10636 1/20 0.53
KMT2A Q03164 4/20 0.52
CYP1A2 P05177 2/20 0.52
CYP2C19 P33261 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
HTT P42858 2/20 0.51
MEN1 O00255 2/20 0.51
GBA1 P04062 1/20 0.51
POLB P06746 1/20 0.51
HPGD P15428 1/20 0.51
PAX8 Q06710 1/20 0.51
TSHR P16473 1/20 0.49
CYP2D6 P10635 2/20 0.47
CNR1 P21554 1/20 0.47
CNR2 P34972 1/20 0.47
ALDH1A1 P00352 2/20 0.47
NPSR1 Q6W5P4 1/20 0.47
HRH3 Q9Y5N1 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4770137 0.83 SMN1; SMN2 (0.51) SMN1; SMN2LMNAMAPTKMT2ACYP1A2
SCHEMBL4772199 0.83 KMT2A (0.54) SMN1; SMN2LMNAMAPTKMT2ACYP1A2
SCHEMBL4773428 0.82 SMN1; SMN2 (0.47) SMN1; SMN2LMNAMAPTKMT2ACYP1A2
SCHEMBL4770241 0.80 SMN1; SMN2 (0.46) SMN1; SMN2LMNAMAPTKMT2ACYP1A2
SCHEMBL4766794 0.79 ALDH1A1 (0.47) SMN1; SMN2LMNAMAPTKMT2ACYP1A2
SCHEMBL4769411 0.79 CHRNA7 (0.59) SMN1; SMN2LMNAMAPTKMT2ACYP1A2
SCHEMBL4772149 0.79 HRH4 (0.56) SMN1; SMN2LMNAMAPTKMT2ACYP1A2
Ethane SCHEMBL4794093 0.78 HTR2C (0.56) SMN1; SMN2LMNAMAPTKMT2ACYP1A2
SCHEMBL4763791 0.78 ABCG2 (0.40) MAPTL3MBTL1GBA1ALDH1A1HRH4
SCHEMBL4073983 0.78 HTR2C (0.59) LMNAMAPTKMT2ACYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1020445-B1 FUSED PYRIDINE DERIVATIVES EISAI R&D MAN CO LTD (JP) 2008-08-13 EP disclosed
EP-1020445-B1 FUSED PYRIDINE DERIVATIVES EISAI R&D MAN CO LTD (JP) 2008-08-13 EP disclosed
US-6875761-B2 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. (JP) 2005-04-05 US disclosed
US-20040204421-A1 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. 2004-10-14 US disclosed
US-6790844-B2 MUSCLE RELAXANTS; ANTISEROTONINE AGENT EISAI CO., LTD (JP) 2004-09-14 US disclosed
US-20020013460-A1 Condensed pyridine compound EISAI CO., LTD 2002-01-31 US disclosed
US-6340759-B1 ANTISPASMODIC AGENTS EISAI CO., LTD. (JP) 2002-01-22 US disclosed
EP-1020445-A1 FUSED PYRIDINE DERIVATIVES Eisai Co., Ltd. (JP) 2000-07-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013460-A1 Condensed pyridine compound MUSK, HTR1A, PAX3 SMN1; SMN2 27/4885LMNA 1057/4885MAPT 1892/4885
US-20040204421-A1 Certain 1,3-disubstituted isoquinoline derivatives MUSK, HTR1A, RYR1 SMN1; SMN2 37/4885LMNA 1917/4885MAPT 3756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.